EXACT Sciences Announces New Management Team Print E-mail
Wednesday, 18 March 2009 15:07

MARLBOROUGH, Mass.--(BUSINESS WIRE)--EXACT Sciences (EXAS) today announced that the .domain_name{float:left; line-height:34px; font-size:26px; font-weight: normal; color:#fff; padding-top:27px; width:535px} company’s board of box-shadow: 0px -1px 10px 0px rgba(0,0,0,0.75);} directors has appointed Kevin T. Conroy as president and chief executive, and Maneesh K. Arora as senior vice president and chief financial officer, effective April 2, 2009. Mr. Conroy is .kwd_bloack ul{padding-bottom:20px} joining the #logo{float:right;width:300px;padding:15px 0 0} company’s board of directors immediately.

 

Click here for my previous article on .custom-msg a { text-decoration: none; color:#CC0000; font-size: 11px} EXAS after the #logo p{text-align:right;clear:both;padding:4px 2px 0 0; color:#aeaeae;} Genzyme (GENZ) deal was announced as part of .frt_arr{float:left;width:223px; height:503px; background-position:0 3px; background-repeat:no-repeat} refusing Sequenom's (SQNM) hostile tender offer for $1.50 per share:

http://biomedreports.com/bloglist/540.html

 

Both Mr. Conroy, 43, and Mr. Arora, 40, bring significant experience with molecular diagnostics and Humspm.com managing complex clinical trials to their new roles at EXACT. They were most recently president and chief executive, and chief financial officer, respectively, of Third Wave Technologies Inc. Third Wave, a NASDAQ-traded molecular diagnostics company, was acquired last year by Hologic Inc. for $582 million.

 

During Mr. Conroy’s tenure as chief executive of .lst_arr{float:left;width:223px; height:503px; background-position:right 3px; background-repeat:no-repeat} Third Wave, he oversaw the #logo p a{color:#ffffff;font-size:11px;text-decoration:underline;} development of .kwd_bloack{float:left; width:514px; margin-top:50px} two human papillomavirus (HPV) molecular diagnostic tests, including their successful clinical trial. The prospective study of .kwd_bloack h4{font-size:13px; line-height:18px; color:#ababab; padding-left: 4px; text-transform: uppercase; text-align: center;} two cancer screening products was one of .kwd_bloack ul, .kwd_bloack ul li{float:left; text-align:center;width:514px;list-style:none} the #logo img{border:0 none;} largest diagnostic trials ever conducted in the .searchbox{float:right; width:351px; height:30px; padding-top:38px} United States, with almost 90 sites. Both of .kwd_bloack ul{padding-top:9px} the Third-Wave-developed HPV tests received U.S. Food and Drug Administration (FDA) approval last week. Mr. Conroy also led Third Wave through the .srch-txt{float:left; width:242px; height:28px; font-size:16px; line-height:28px; background:url(http://i3.cdn-image.com/__media__/pics/7867/srch-bg.gif) 7px 5px no-repeat #fff; color:#414141; padding: 0 5px 0 30px; border:1px solid #6f6f6f; outline:none} successful clinical trial of .kwd_bloack ul li{line-height:30px} its InPlex cystic fibrosis test, which received FDA clearance in March 2008.

 

“Kevin and Maneesh have a proven track record of .kwd_bloack ul li a{float:left;width:510px;text-decoration:underline; font-size:24px; font-weight:bold; color:#ffb047; display:block; word-wrap: break-word; padding: 10px 0} creating outstanding customer and shareholder value by setting clear corporate priorities and